On July 8, 2022 Neuren Pharmaceuticals (ASX: NEU) reported the appointment of Liza A. Squires M.D. to the new position of Chief Medical Officer, based in the United States (Press release, Neuren, JUL 8, 2022, View Source;[email protected] [SID1234616565]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Squires is a board certified physician in General Pediatrics and Neurology with Special Competence in Child Neurology. Over the past 20 years, she has held positions of increasing responsibilities in both early and late-stage development at Johnson and Johnson, Shire Pharmaceuticals, Lumos Pharma, Aevi Genomic Medicine and Origin Biosciences. She has led and contributed to multiple New Drug Applications resulting in global regulatory approvals and has extensive experience in orphan drug development.

Dr Squires trained in general pediatrics at Yale University and did her residency in Child Neurology at Massachusetts General Hospital.

Neuren CEO Jon Pilcher commented: "I am very pleased to welcome Liza at such an exciting time for Neuren. Her ideal skills and experience in pediatric neurology and orphan drug development will make a big difference to the team as we advance our ambitious plans for NNZ-2591 in multiple indications."